Gastro-oesophageal reflux disease

Lancet

Volumn 367, Issue 9528, 2006, Pages 2086-2100

  Moayyedi, Paul ^a   Talley, Nicholas J ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BARIUM; COPOLYMER; HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO; POLYETHYLENE; POLYVINYL ALCOHOL; PROTON PUMP INHIBITOR;

CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; ENDOSCOPIC THERAPY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEREDITY; HUMAN; INCIDENCE; LONG TERM CARE; LOWER ESOPHAGUS SPHINCTER; META ANALYSIS; MORBIDITY; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PH MEASUREMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; STOMACH FUNDOPLICATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

EID: 33745195704     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68932-0     Document Type: Review

References (193)

1. Sandler R., Everhart J., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 122 (2002) 1500-1511
2. Dent J., Armstrong D., Delaney B., Moayyedi P., Talley J., and Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 53 (2004) 1-24
3. DeVault K., and Castell D. American College of Gastroenterology updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
4. Anon. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 44 suppl 2 (1999) S1-S16
5. Junghard O., Carlsson R., and Lind T. Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials. Scand J Gastroenterol 38 (2003) 1197-1199
6. Lundell L., Dent J., Bennett J., et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45 (1999) 172-180
7. Kahrilas P. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 98 3 suppl (2003) S15-S23
8. Moayyedi P., and Axon A. Gastro-oesophageal reflux disease: the extent of the problem. Aliment Pharmacol Ther 22 suppl 1 (2005) 11-19
9. Dent J., El-Serag H., Wallander M.-A., and Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54 (2005) 710-717
10. Kang J. Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 20 (2004) 705-717
11. Shaheen N., and Provenzole D. The epidemiology of gastroesophageal reflux disease. Am J Med Sci 326 (2003) 264-273
12. Hu W., Hui W., Lam C., and Lam S. Anxiety and depression are co-factors determining health care utilisation in patients with dyspepsia: a Hong Kong population based study. Gastroenterology 112 suppl 1 (1997) A153
13. Ronkainen J., Aro P., Storskrubb T., et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 40 (2005) 275-285
14. Wienbeck M., and Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol 156 suppl (1989) 7-13
15. Locke III G., Talley N., Fett S., Zinsmeister A., and Melton III L. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112 (1997) 1448-1456
16. Kennedy T., and Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 14 (2000) 1589-1594
17. Diaz-Rubio M., Moreno-Elola-Olaso C., Rey E., Locke III G., and Rodriguez-Artalejo F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther 19 (2004) 95-105
18. Agreus L., Svardsudd K., Talley N., Jones M., and Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 96 (2001) 2905-2914
19. Johnson D., and Fennerty M. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 126 (2004) 660-664
20. Ford A., Forman D., Reynolds P., Cooper B., and Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 162 (2005) 454-460
21. Barak N., Ehrenpreis E., Harrison J., and Sitrin M. Gastro-oesophageal reflux disease in obesity: pathophysiology and therapeutic considerations. Obes Rev 3 (2002) 9-15
22. Wajed S., Streets C., Bremner C., and DeMeester T. Elevated body mass disrupts the barrier to gastroesophageal reflux. Arch Surg 136 (2001) 1014-1018
23. Kahrilas P., and Gupta R. Mechanisms of acid reflux associated with cigarette smoking. Gut 31 (1990) 4-10
24. Vitale G., Cheadle W., Patel B., Sadek S., Michel M., and Cuschieri A. The effect of alcohol on nocturnal gastroesophageal reflux. JAMA 258 (1987) 2077-2079
25. Thomas F., Steinbaugh J., Fromkes J., Mekhjian H., and Caldwell J. Inhibitory effect of coffee on lower esophageal sphincter pressure. Gastroenterology 79 (1980) 1262-1266
26. Murphy D., and Castell D. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol 83 (1988) 633-636
27. Holloway R., Lyrenas E., Ireland A., and Dent J. Effect of intraduodenal fat on lower oesophageal sphincter function and gastro-oesophageal reflux. Gut 40 (1997) 449-453
28. Hampel H., Abraham N., and El-Serag H. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143 (2005) 199-211
29. Stene-Larsen G., Weberg R., Froyshov Larsen I., Bjortuft O., Hoel B., and Berstad A. Relationship of overweight to hiatus hernia and reflux oesophagitis. Scand J Gastroenterol 23 (1988) 427-432
30. Avidan B., Sonnenberg A., Schnell T., and Sontag S. Risk factors for erosive reflux esophagitis: a case-control study. Am J Gastroenterol 96 (2001) 41-46
31. Lee S., Song C., Jeen Y., et al. Prevalence of endoscopic reflux oesophagitis among Koreans. J Gastroenterol Hepatol 16 (2001) 373-376
32. Kang J., and Ho K. Different prevalences of reflux oesophagitis and hiatus hernia among dyspeptic patients in England and Singapore. Eur J Gastroenterol Hepatol 11 (1999) 845-850
33. Lagergren J., Bergstrom R., and Nyren O. No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. Gut 47 (2000) 26-29
34. Locke G., Talley N., Fett S., Zinsmeister A., and Melton J. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 106 (1999) 642-649
35. Haque M., Wyeth J., Stace N., Talley N., and Green R. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. NZ Med J 113 (2000) 178-181
36. Terry P., Lagergren J., Wolk A., and Nyren O. Reflux-inducing dietary factors and risk of adenocarcinoma of the esophagus and gastric cardia. Nutr Cancer 38 (2000) 186-191
37. El-Serag H., Satia J., and Rabeneck L. Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut 54 (2005) 11-17
38. Ruhl C., and Everhard J. Overweight, but not high dietary fat intake, increases risk of gastro-oesophageal reflux disease hospitalisation: the NHANES I epidemiologic follow up study. Ann Epidemiol 9 (1999) 424-435
39. El-Serag H., and Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 43 (1998) 327-333
40. Raghunath A., Hungin A., Wooff D., and Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 326 (2003) 737
41. Raghunath A., Hungin A., Wooff D., and Childs S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 20 (2004) 733-744
42. Moayyedi P., Feltbower R., Brown J., et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet 355 (2000) 1665-1669
43. Harvey R., Lane J., Murray L., Harvey I., Donovan J., and Nair P. Randomised controlled trial of the effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: the Bristol Helicobacter Project. BMJ 328 (2004) 1417-1419
44. Delaney B., and Moayyedi P. Eradicating H. pylori does not cause gastro-oesophageal reflux disease. BMJ 328 (2004) 1388-1389
45. Trudgill N., Kapur K., and Riley A. Familial clustering of reflux symptoms. Am J Gastroenterol 94 (1999) 1172-1178
46. Romero Y., Cameron A., Locke III G., et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 113 (1997) 1449-1456
47. Cameron A., Lagergren J., Henriksson C., Nyren O., Lock III G., and Pedersen N. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 122 (2002) 55-59
48. Mohammed I., Cherkas L., Riley S., Spector T., and Trudgill N. Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut 52 (2003) 1085-1089
49. Kahrilas P. GERD pathogenesis, pathophysiology and clinical manifestations. Cleve Clin J Med 70 suppl 5 (2003) S4-S19
50. Dent J. Patterns of lower esophageal sphincter function associated with gastroesphageal reflux. Am J Med 103 suppl 5A (1997) 29S-32S
51. Pandolfino J., Shi G., Trueworthy B., and Kahrila P. Esophagastric junction opeing during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 125 (2003) 1018-1024
52. Richter J. Do we know the cause of reflux disease?. Eur J Gastroenterol Hepatol 11 suppl 1 (1999) S3-S9
53. Kahrilas P., Shi G., Manka M., and Joehl R. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 118 (2000) 688-695
54. Jones M., Sloan S., Rabine J., Ebert C., Huang C., and Kahrilas P. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 96 (2001) 1711-1717
55. Fletcher J., Wirz A., Henry E., and McColl K. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut 53 (2004) 168-173
56. Vaezi M., and Richter J. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 111 (1996) 1192-1199
57. Kahrilas P., Dodds W., and Hogan W. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology 94 (1988) 73-80
58. Suzuki H., Iijima K., Scobie G., Fyfe V., and McColl K. Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. Gut 54 (2005) 1527-1535
59. Orlando R. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility and acid exposure. Am J Gastroenterol 92 suppl 4 (1997) S3-S5
60. Trimble K., Pryde A., and Heading R. Lowered oesophageal sensory threshold in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 37 (1995) 7-12
61. Barlow W., and Orlando R. The pathogenesis of heartburn in nonerosive disease: a unifying hypothesis. Gastroenterology 128 (2005) 771-778
62. Pehlivanov N., Liu J., and Mittal R. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 280 (2001) G743-G751
63. Moayyedi P., Duffy J., and Delaney B. New approaches to enhance the accuracy of the diagnosis of reflux disease. Gut 53 (2004) 55-57
64. Richter J. Diagnostic tests for gastroesophageal reflux disease. Am J Med Sci 326 (2003) 300-308
65. Zaman A., Hapke R., Sahagun G., and Katon R. Unsedated peroroal endoscopy with a video ultrathin endoscope: patient acceptance, tolerance and diagnostic accuracy. Am J Gastroenterol 93 (1998) 1260-1263
66. Nakamura T., Shirakawa K., Masuyama H., Sugaya H., Hiraishi H., and Terano A. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther 21 suppl 2 (2005) 19-26
67. Jones B., Fleischer D., Sharma V., et al. Yield of repeat wireless video capsule endoscopy in patients with obscure gastrointestinal bleeding. Am J Gastroenterol 100 (2005) 1058-1064
68. Neu B., Wettschureck E., and Rosch T. Is esophageal capsule endoscopy feasible? Results of a pilot. Endoscopy 35 (2003) 957-961
69. Eliakim R., Sharma V., Yassin K., et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol 39 (2005) 572-578
70. Riddell R. The biopsy diagnosis of gastroesophageal reflux disease, "carditis" and Barrett's esophagus, and sequelae of therapy. Am J Surg Pathol 20 suppl 1 (1996) S31-S50
71. Caviglia R., Ribolsi M., Maggiano N., et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 100 (2005) 543-548
72. Wong W.-M., and Wong B.-Y. Definition and diagnosis of gastroesophageal reflux disease. J Gastroenterol Hepatol 19 suppl 3 (2004) S26-S32
73. Thomson A., Barkun A., Armstrong D., et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric treatment-prompt endoscopy (CADET-PE) study. Aliment Pharmacol Ther 17 (2003) 1481-1491
74. Klauser A., Schindlbeck N., and Müller-Lissner S. Symptoms in gastro-oesophageal reflux disease. Lancet 335 (1990) 205-208
75. Moayyedi P., and Axon A. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol 94 (1999) 3122-3125
76. Moayyedi P., Talley N., Fennerty M., and Vakil N. Can the clinical history distinguish between organic and functional dyspepsia?. JAMA 295 (2006) 1566-1576
77. Danish Dyspepsia Study Group. Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol 96 (2001) 1417-1421
78. Barenys M., Abad A., Pons J., et al. Scoring system has better discriminative value than Helicobacter pylori testing in patients with dyspepsia in a setting with high prevalence of infection. Eur J Gastroenterol Hepatol 12 (2000) 1275-1282
79. Bytzer P., Hansen J., Havelund T., Malchow-Moller A., and Schaffalitzky De Muckadell O. Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement. Eur J Gastroenterol Hepatol 8 (1996) 359-363
80. Hansen J., Bytzer P., and Schaffalitzky De Muckadell O. Management of dyspeptic patients in primary care: value of the unaided clinical diagnosis and of dyspepsia subgrouping. Scand J Gastroenterol 33 (1998) 799-805
81. Heikkinen M., Pikkarainen P., Takala J., Rasanen H., and Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol 30 (1995) 519-523
82. Fjosne U., Kleveland P., Waldum H., Halvorsen T., and Petersen H. The clinical benefit of routine upper gastrointestinal endoscopy. Scand J Gastroenterol 21 (1986) 433-440
83. Numans M., and de Wit N. Reflux symptoms in general practice: diagnostic evaluation of the Carlsson-Dent gastro-oesophageal reflux disease questionnaire. Aliment Pharmacol Ther 17 (2003) 1049-1055
84. Kahrilas P., and Quigley E. Clinical esophageal pH recording: a technical review for practice guidelines development. Gastroenterology 110 (1996) 1982-1996
85. Vela M., Camacho-Lobato L., Srinivasan R., Tutuian R., Katz P., and Castell D. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 120 (2001) 1599-1606
86. Remes-Troche J., Ibarra-Palomino J., Carmona-Sanchez R., and Valdovinos M. Performance, tolerability, and symptoms related to prolonged pH monitoring using the Bravo system in Mexico. Am J Gastroenterol 100 (2005) 2382-2386
87. Pandolfino J., and Kahrilas P. Prolonged pH monitoring: Bravo capsule. Gastrointest Endosc Clin N Am 15 (2005) 307-318
88. US Food and Drug Administration. Center for Devices and Radiological Health. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.cfm (accessed Aug 30, 2005)
89. Johnston B., Troshinsky M., Castell J., and Castell D. Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Am J Gastroenterol 91 (1996) 1181-1185
90. Numans M., Lau J., de Wit N., and Bonis P. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 140 (2004) 518-527
91. Sonnenberg A., and El-Serag H. Clinical epidemiology and natural history of gastroesophagal reflux disease. Yale J Biol Med 72 (1999) 81-92
92. El-Serag H., and Sonnenberg A. Outcome of erosive reflux esophagitis after Nissen fundoplication. Am J Gastroenterol 94 (1999) 1771-1776
93. Fennerty M. The continuum of GERD complications. Cleve Clin J Med 70 suppl 5 (2003) S33-S50
94. Jankowski J., Harrison R., Perry I., et al. Seminar: Barrett's metaplasia. Lancet 356 (2000) 2079-2085
95. Lieberman D., Oehlke M., Helfand M., and GORGE Consortium. Risk factors for Barrett's esophagus in community based practice. Am J Gastroenterol 92 (1997) 1293-1297
96. Smith K., O'Brien S., Smithers B., et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 14 (2005) 2481-2486
97. Shaheen N., Crosby M., Bozymski E., and Sandler R. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 119 (2000) 333-338
98. Jankowski J., Provenzale D., and Moayyedi P. Oesophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology 122 (2002) 588-590
99. Shaheen N., and Ransohoff D. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA 287 (2002) 1972-1981
100. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroeophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
101. Chow W.-H., Finkle W., McLaughlin J., et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274 (1995) 474-477
102. Farrow D., Vaughan T., Sweeney C., et al. Gastro-oeosphageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 11 (2000) 231-238
103. Lagergren J., Ye W., Bergstrom R., and Nyren O. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA 284 (2000) 961-962
104. Napierkowski J., and Wong R. Extraesophageal manifestations of GERD. Am J Med Sci 326 (2003) 285-299
105. Moayyedi P., Delaney B., and Forman D. Gastro-oesophageal reflux disease. Clin Evidence 11 (2004) 583-600
106. Khan M, Santana J, Donellan C, Preston C, Moayyedi P. Pharmacological therapies in the short term treatment of oesophagitis. Cochrane Database Syst Rev (in press).
107. Dobrilla G., Chillovi F., Tafner G., et al. Treatment of erosive reflux oesophagitis: a double blind multicentre trial with nizatidine 300 mg b.i.d vs placebo. Ital J Gastroenterol 24 (1992) 338-341
108. Goy J., Maynard J., McNaughton W., and O' Shen A. Ranitidine and placebo in the treatment of reflux oesophagitis. Med J Aust 2 (1983) 558-561
109. Hine K., Holmes G., Melikian V., Lucey M., and Fairclough P. Ranitidine in reflux oesophagitis. Digestion 29 (1984) 119-123
110. Lehtola J., Niemela S., Martikainen J., and Krekala I. Scand J Gastroenterol 21 (1986) 175-180
111. Palmer R., Frank W., Rockhold F., Wetherington J., and Young M. Cimetidine 800 mg twice daily for healing of erosion and ulcer in gastroesophageal reflux disease. J Clin Gastroenterol 12 (1990) s29-s34
112. Quik R., Cooper M., Gleeson M., et al. A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis. Aliment Pharmacol Therapeutics 4 (1990) 201-211
113. Sabesin S., Berlin R., Humphries T., et al. Famotidine relieves symptoms of Gastroesophageal reflux disease and heals erosions and ulceration. Arch Intern Med 151 (1991) 2394-2400
114. Shrebaniuk R., Bailey W., Grace T., et al. Ranitidine in the treatment of symptomatic Gastreosophageal reflux disease. J Clin Gastroenterol 6 (1984) 9-15
115. Simon T., Berenso H., Berlin R., Snapinn S., and Cagolla A. Randomized, placebo-controlled comparison of famotidine 20 mg bd or 40 mg bd, in patients with erosive eosophagitis. Aliment Pharmacol Ther 8 (1994) 71-79
116. Sontag S., Robinsson M., McCallum R., Barwick K., and Nardi R. Ranitidine therapy for Gastro-sophageal reflux disease. Arch Intern Med 147 (1987) 1758-1765
117. Kar P., Gurtoo A., Jain S., Narula M., and Jain A. Ranitidine vs placebo: a double blind trial in the management of reflux oesophagitis. Curr Ther Res 47 (1990) 731-733
118. Roufail W., Belsito A., Robinson M., Barish C., Rubin A., and Glaxo erosive esophagitis study group. Aliment Pharmacol Ther 6 (1992) 597-607
119. Silver M., Murdock R., Morrill B., and Sur S. Ranitidine 300 mg twice daily and 150 mg four times daily are effective in healing erosive oesophagitis. Aliment Pharmacol Ther 10 (1996) 373-380
120. Breen K., Desmond P., and Whelan G. Treatment of reflux oesophagitis: a randomized, controlled evaluation of cimetidine. Med J Aust 2 (1983) 555-556
121. Brown P. Cimetidine in the treatment of reflux oesophagitis. Med J Aust 2 (1979) 96-97
122. Festen H., Driessen W., Lamers C., and Van Tongeren J. Cimetidine in the treatment of severe ulcerative reflux oesophagitis: results of an 8-week double-blind study and of subsequent long term maintenance treatment. Neth J Med 23 (1980) 237-240
123. Johansson K., Boeryd B., Johansson K., and Tibbling L. Double-blind cross over study of ranitidine and placebo in gastro-oesophageal reflux disease. Scand J Gastroenterol 21 (1986) 769-778
124. Wesdrop E., Bartelsman J., Pape K., Dekker W., and Tytgat N. Cimetidine in reflux oesophagitis: a double blind controlled trial. Gastroenterology 74 (1978) 821-823
125. Cloud M., Enas N., Humphries T., Bassion S., and The Rabeprazole study group. Rabeprazole in the treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer and GERD. Digest Dis Sci 43 (1998) 993-1000
126. Earnest D., Dorsch E., Jones J., Jennigs D., and Greski-Rose P. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 93 (1998) 238-243
127. Hetzel D., Dent J., Reed W., et al. Healing & relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95 (1988) 903-912
128. Richter J., Bochenek W., and Panatoprazole US GERD study group. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Am J Gastroenterol 95 (2000) 3071-3079
129. Sontag S., Hirschowitz B., Holt S., et al. Two doses of omeprazole vs placebo in symptomatic erosive esophagitis: the US multicenter study. Gastroenterology 102 (1992) 109-118
130. Armbrecht U., Abucar A., Hameeteman W., Schneider A., and Stockbrugger W. Treatment of reflux oesophagitis of moderate & severe grade with ranitidine or pantoprazole: comparison of 24 hour intragastric & oesophageal pH. Aliment Pharmacol Ther 11 (1997) 959-965
131. Armstrong D., Chir B., Pare P., Pericak D., Pyzyk M., and the Canadian pantoprazole GERD Study Group. Symptom relief in the gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 96 (2001) 2849-2857
132. Bardhan K., Hawkey C., Long R., et al. Lansoprazole vs ranitidine for the treatment of reflux oesophagitis. Aliment Pharmacol Ther 9 (1995) 145-151
133. Dehn T., Shepherd H., Colin-Jones D., Kettlewell M., and Carroll N. Double blind comparison of omeprazole vs cimetidine in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut 31 (1990) 509-513
134. Dettmer A., Vogt R., Sielaff F., Luhmann R., and Scheinder A. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild oesophagitis. Aliment Pharmacol Ther 12 (1998) 865-872
135. Duvnjak M., Virovic L., and Supanc V. Efficacy of pantoprazole compared with ranitidine in the treatment of gastroesophageal reflux disease: an open labelled randomized parallel and longitudinal comparative trial. Pharmaca 40 (2002) 199-206
136. Farley A., Wruble L., and Humphries T. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double blind, randomized clinical trial. Am J Gastroenterol 95 (2000) 1894-1895
137. Feldman M., Harford W., Fisher R., et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+) ATPase inhibitor: a controlled double blind study. Am J Gastroenterol 88 (1993) 1212-1217
138. Green J., Tildesley G., Theodossi A., et al. Omeprazole 20 mg to 40 mg once daily is more effective than ranitidine 300 mg to 600 mg daily in providing complete symptom relief and endoscopic healing in patients with reflux oesophagitis. Br J Clin Res 6 (1995) 63-76
139. Havelund T., Laursen L., Kristensen E., et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: a double blind comparative trial. BMJ 296 (1988) 89-92
140. Italian Reflux Oesophagitis Study Group. Omeprazole produces significantly greater healing of erosive of ulcerative reflux oesophagitis than ranitidine. Eur J Gastroenterol Hepatol 3 (1991) 511-517
141. Jansen J., and van Oene J. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. Aliment Pharmacol Ther 13 (1999) 1611-1620
142. Kwano S., Murata H., Tsuji S., et al. Reflux esophagitis: natural history and treatment: randomized comparative study of omeprazole and famotidine in reflux esophagitis. J Gastroenterol Hepatol 17 (2002) 955-959
143. Klinkenburg Knol E., Jansen J., Festen H., Meuwissen S., and Lamers C. Double-blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1 (1987) 349-351
144. Koop H., Schepp W., Dammann H., Schneider A., Luhmann R., and Classen M. Comparative trial of Pantoprazole and ranitidine in the treatment of reflux oesophagitis. J Clin Gastroenterol 20 (1995) 192-195
145. Kovacs T., Wilcox C., Devault K., Miska D., Bochenek W., and Pantoprazole US study group. Comparison of the efficacy of pantoprazole vs nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther 16 (2002) 2043-2052
146. Menchen P., Malagelada J., Armengol J., et al. Clinical efficacy and safety of pantoprazole versus ranitidine with gastro-oesophageal reflux disease: Spanish multicenter study. Gastroenterology 118 (2000) 1274
147. Meneghelli U., Boaventura S., Moraes-Filho J., et al. Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection. Dis Esophagus 15 (2002) 50-56
148. Pare P., Armstrong D., Pericak M., and Pyzyk M. Pantoprazole rapidly improves health related quality of life in patients with heartburn. J Clin Gastroenterol 37 (2003) 132-138
149. Petite J., Aucomte A., Barbare C., et al. Lansoprazole versus ranitidine dans le traitement de l' oesophagite peptique par reflux: etude multicentrique. Med Chir Dig 20 (1991) 462-468
150. Robinson M., Sahba B., Avner D., Jhala N., Greski-Rose P., and Jennings D. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 9 (1995) 25-31
151. Robinson M., Decktor D., Maton P., et al. Omeprazole is superior to ranitidine plus metoclopramide in the short term treatment of erosive oesophagitis. Aliment Pharmacol Ther 7 (1993) 67-73
152. Sandmark S., Carlson R., Fausa O., and Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 23 (1988) 625-632
153. Van Zyl J., Grundling H., van Rensburg C., et al. Efficacy and tolerabiity of 20 mg pantoprazole vs 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. Eur J Gastroenterol Hepatol 12 (2000) 197-202
154. Vantrappen G., Rutgeerts L., Schurmans P., and Coenegrachts J.-L. Omeprazole 40 mg is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 33 (1988) 523-529
155. Zeitoun P., Desjars De Keranroué N., and Isal J. Omeprazole versus ranitidine in erosive oesophagitis. Lancet 330 (1987) 621-622
156. Johnson D., Orr W., Crawley J., et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 100 (2005) 1914-1922
157. van Pinxteren B., Numans M., Bonis P., and Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 3 (2004) CD002095
158. Dean B., Gano Jr. A., Knight K., Ofman J., and Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2 (2004) 656-664
159. Donnellan C., Sharma N., Preston C., and Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 4 (2004) CD003245
160. Zacny J., Zamakhshary M., Sketris I., and Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 21 (2005) 1299-1312
161. Pace F., Negrini C., Wiklund I., Rossi C., Savarino V., and The Italian ONE investigators study group. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 22 (2005) 349-356
162. Sjostedt S., Befrits R., Sylvan A., et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 22 (2005) 183-191
163. Cremonini F., Wise J., Moayyedi P., and Talley N. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta-analysis. Am J Gastroenterol 100 (2005) 1226-1232
164. Wang W., Huang J., Zheng G., et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? A meta-analysis. Arch Intern Med 165 (2005) 1222-1228
165. Chang A., Lasserson T., Gaffney J., Connor F., and Garske L. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2 (2005) CD004823
166. Gibson P., Henry R., and Coughlan J. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 1 (2003) CD001496
167. Vakil N., and Sharma P. Review article: endoscopic treatments for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 17 (2003) 1427-1434
168. Mahmood Z., McMahon B., Arfin Q., et al. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow-up. Gut 52 (2003) 34-39
169. Mahmood Z., Byrne P., McMahon B., et al. Comparison of transoesophageal endoscopic plication (TEP) with laparoscopic nissen fundoplication (LNF) in the treatment of uncomplicated reflux disease. Am J Gastroenterol 101 (2006) 431-436
170. Triadafilopoulos G., DiBaise J., Nostrant T., et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Gastrointest Endosc 55 (2002) 149-156
171. Johnson D., Aisenberg A., Cohen L., et al. Enteryx, an injectable treatment of GERD - multi-centre results. Am J Gastroenterol 97 (2002) S12
172. Aghazahedi M, Talley NJ, Moayyedi P. Endoscopic therapy for patients with gastro-oesophageal reflux disease (protocol). Cochrane Database Syst Rev (in press).
173. Corley D., Katz P., Wo J., et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 125 (2003) 668-676
174. Deviere J., Costamagna G., Neuhaus H., et al. Enteryx for the treatment of GERD: 12 months follow-up results of a randomized, sham controlled, multicenter trial. Gastroenterology 128 (2005) A45
175. Park P.-O., Hall-Angeras M., Ohlin B., et al. A prospective, multicenter, randomized, single-blind, parallel group study on the comparison between endoscopic cardia suturing and sham operation as a treatment of patients with gastroesophageal reflux symptoms. Gastroenterology 128 (2005) A95
176. Schwartz M., Wellink H., Gooszen H., Samson M., and Smout A. A blinded, randomized, sham-controlled trial of endoscopic gastroplication for the treatment of gastro-esophageal reflux disease (GERD): preliminary results. Gastrointest Endosc 61 (2005) AB95
177. Rothstein R., Hynes M., Grove M., and Pohl H. Endoscopic gastric placation (Endocinch) for GERD: a randomized, sham-controlled, blinded, single centre study. Gastrointest Endosc 59 (2004) AB111
178. Allgood P., and Bachmann M. Medical or surgical treatment for chronic gastro-oesophageal reflux? A systematic review of published evidence of effectiveness. Eur J Surg 166 (2000) 713-721
179. Lundell L., Miettinen P., Myrvold H., et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 192 (2001) 172-181
180. Catarci M., Gentileschi P., Papi C., et al. Evidence-based appraisal of antireflux fundoplication. Ann Surg 239 (2004) 325-337
181. Finlayson S., Laycock W., and Birkmeyer J. National trends in utilization and outcomes of antireflux surgery. Surg Endosc 17 (2003) 864-867
182. Flum D., Koepsell T., Heagerty P., and Pellegrini C. The nationwide frequency of major adverse outcomes in antireflux surgery and the role of surgeon experience, 1992-1997. J Am Coll Surg 195 (2002) 611-618
183. Spechler S., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. JAMA 285 (2001) 2331-2338
184. Tran T., Spechler S., Richardson P., and El-Serag H. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastroenterol 100 (2005) 1002-1008
185. National Institute of Clinical Excellence. Dyspepsia: management of dyspepsia in adults in primary care. http://www.nice.org.uk/pdf/CG017NICEguideline.pdf (accessed Sept 5, 2004)
186. Fock K., Talley N., Hunt R., et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol 19 (2004) 357-367
187. Veldhuyzen van Zanten S., Bardette M., Chiba N., et al. Evidence-based recommendations for the short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 19 (2005) 285-303
188. Katelaris P., Holloway R., Talley N., Gotley D., Williams S., and Dent J. Gastro-oesophageal reflux disease in adults: guidelines for clinicians. J Gastroenterol Hepatol 17 (2002) 825-833
189. Vakil N., Talley N., Moayyedi P., and Fennerty M. The diagnostic value of alarm features in predicting upper gastrointestinal malignancy in dyspeptic patients: systematic review and meta-analysis. Gastroenterology 128 (2005) A-80
190. Vaezi M. Refarctory GERD: acid, nonacid, or not GERD?. Am J Gastroenterol 99 (2004) 989-990
191. Inadomi J., McIntyre L., Bernard L., and Fendrick A. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 98 (2003) 1940-1944
192. Lee T., Fennerty M., and Howden C. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?. Aliment Pharmacol Ther 20 (2004) 1241-1251
193. Dent J., Jones R., Kahrilas P., and Talley N. Management of gastro-oesophageal reflux disease in general practice. BMJ 322 (2001) 344-347